Racura Oncology (RAC) Investor Presentation summary

Corporate overview and financials

• ASX-listed clinical-stage biopharmaceutical company focused on cancer care, with a market capitalization of $296.5 million and $17.2 million cash at bank as of June 2024.

• No debt and an enterprise value of $279.3 million; 170.4 million shares and 35.2 million options on issue.

• Bonus and piggyback options issued in November 2023 could raise up to $25 million before May 2026.

Leadership and management

• Board and management team have extensive experience in biotech, oncology, and pharmaceutical development.

• Key executives include Dr. Daniel Tillett (CEO), Dr. Peter Smith (Executive Chair), and Dr. Michelle Rashford (Chief Medical Officer).

• Team members have backgrounds at major institutions such as Roche, Novartis, and CSL.

Market opportunity and unmet need

• Anthracyclines are widely used but limited by permanent cardiovascular toxicity, especially in children and high-risk patients.

• Chemotherapy patients have a 37% increased risk of cardiovascular disease; single doses can cause heart damage.

• Global anthracycline use is growing at a 6.6% CAGR, with broad application across multiple cancer types.